Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Case Report

Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C

Jong Wook Choi, June Sung Lee, Woo Hyun Paik, Tae Jun Song, Jung Wook Kim, Won Ki Bae, Kyung-Ah Kim, Jung Gon Kim

Clin Mol Hepatol. 2016;22(1):168-171. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.168

View: 9922 Download: 82 Web of Science: 5 Crossref: 7

Original Article

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

Byung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim

Clin Mol Hepatol. 2012;18(3):272-278. Published online September 25, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.3.272

View: 7697 Download: 41 Crossref: 1

Review

Recent trends in the treatment of chronic hepatitis C

Dae Won Jun, Won Young Tak, Si Hyun Bae, Youn Jae Lee

Clin Mol Hepatol. 2012;18(1):22-28. Published online March 22, 2012

DOI: https://doi.org/10.3350/kjhep.2012.18.1.22

View: 10350 Download: 65 Crossref: 9

Original Article

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh

Clin Mol Hepatol. 2011;17(3):220-225. Published online September 30, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.3.220

View: 7470 Download: 53 Crossref: 11

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin

Sang Bun Choi, Youn Jae Lee, Jae Ik Lee, Young Jin Song, Byoung Jin Choi, Jong Han Kim, Eun Uk Jung, Sung Jae Park, Sang Heon Lee, Ji Hyun Kim, Jung Sik Choi, Sam Ryong Jee, Sang Yong Seol

Clin Mol Hepatol. 2011;17(3):183-188. Published online September 30, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.3.183

View: 7348 Download: 37 Crossref: 3

4

Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C

Hyung Min Kang, M.D., Myung Jin Park, M.D. Jeong-Min Hwang, M.D. Jin Wook Kim, M.D., Sook-Hyang Jeong, M.D.

Clin Mol Hepatol. 2009;15(2):209-215. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.209

View: 4775 Download: 37 Crossref: 3

A case report of treatment with pegylated interferon alpha for Lamivudine-resistant chronic hepatitis B virus infection

Won Haing Hur , Hyun Young Woo , Soung Won Jeong , Chan Ran You , Si Hyun Bae , Jong Young Choi , Seung Kew Yoon

Clin Mol Hepatol. 2008;14(4):513-518. Published online December 31, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.4.513

View: 4830 Download: 32 Crossref: 1

1

Treatment of Chronic Hepatitis C: Shorter Treatment Duration For Genotype 2 or 3 Infection

Sook Hyang Jeong

Clin Mol Hepatol. 2007;13(3):301-303. Published online September 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.3.301

View: 3484 Download: 19

4

A Case of Bell`s Palsy Associated with Peginterferon Alfa-2a and Ribavirin Therapy for Chronic Hepatitis C Virus Infection

Moo Yeol Lee, M.D., Hoon Cho, M.D., Yeong Muk Kim, M.D., and Joon Sang Lee, M.D.

Clin Mol Hepatol. 2006;12(3):444-448. Published online January 1, 2000

View: 2730 Download: 17

1 |

Viewed By 4934	MAFLD: How is it different from NAFLD?
Viewed By 4828	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4728	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4446	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4402	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 95	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search